Holen Sie sich die Stockscreener-App
15.74
0.88%
-0.14
Handel nachbörslich:
22.00
6.26
+39.77%
Schlusskurs vom Vortag:
$15.88
Offen:
$15.54
24-Stunden-Volumen:
14.43M
Relative Volume:
0.65
Marktkapitalisierung:
$3.59B
Einnahmen:
$1.78B
Nettoeinkommen (Verlust:
$164.40M
KGV:
22.81
EPS:
0.69
Netto-Cashflow:
$236.51M
1W Leistung:
+8.40%
1M Leistung:
-31.62%
6M Leistung:
-67.49%
1J Leistung:
-54.23%
1-Tages-Spanne:
$15.21
$15.84
1-Wochen-Bereich:
$14.31
$16.91
52-Wochen-Spanne:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
15.74 | 3.62B | 1.78B | 164.40M | 236.51M | 0.69 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.88 | 56.11B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
121.43 | 51.60B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.28 | 46.00B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.05 | 36.98B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
478.16 | 21.26B | 3.13B | 1.27B | 1.12B | 26.39 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
HIMS Stock Rises Premarket: Investors Brush Off JPMorgan Stake Cut Amid FDA GLP-1 Crackdown - Stocktwits
Has The Pullback In Hims & Hers Health (HIMS) Opened Up A Valuation Opportunity? - Yahoo Finance
Barclays lowers its price target on Hims & Hers Health, Inc. (HIMS) to $25 and keeps an overweight rating - MSN
Barclays Lowers its Price Target on Hims & Hers Health, Inc. (HIMS) to $25 and Keeps an Overweight Rating - Finviz
JPMorgan Chase Reduces Stake in Hims & Hers Health to 1.7% - marketscreener.com
Hims and Hers Expands Its Technology Driven Consumer Health Platform - Zacks Investment Research
Hims & Hers Health (HIMS) Leads as Most Shorted Stock Among Mid-to-Large Caps - GuruFocus
Hims & Hers Finds A GLP-1 Hedge? HIMS Stock Rallies As RFK Jr. Signals Peptide Clearances - Stocktwits
Locally-owned pharmacy stops stocking GLP-1 medications, calls out insurance practices - AOL.com
Hims & Hers Snaps EPS Losing Streak but Shares Still in Free Fall - AOL.com
Hims & Hers Health Hits Major Milestones With Strategic Expansion - timothysykes.com
Hims Hers Health 59% Revenue Growth Meets Margin Pressure From Global Expansion - Smartkarma
Hims & Hers Slips as FDA Targets GLP-1 Compounders - GuruFocus
Hims & Hers Health stock: Technical indicators reflect volatility as price gains 4.14% - Traders Union
The Compounding Cliff: Hims & Hers Faces Reckoning as FDA and Big Pharma Close GLP-1 Loopholes - FinancialContent
Hims & Hers Health (HIMS) Faces High Short Interest Amid Sector Trends - GuruFocus
CI Investments Inc. Has $11.71 Million Position in Hims & Hers Health, Inc. $HIMS - MarketBeat
Canaccord Lowers Hims & Hers Health, Inc. (HIMS) Price Target Patent Amid Dispute and FDA Scrutiny - Insider Monkey
Hims Stock Slips Overnight As FDA Warns Telehealth Firms Over GLP-1 Claims — Why Traders Think The ‘Overhang’ Won’t Last - Stocktwits
Hims & Hers (HIMS) Faces Setback as FDA Issues Warning Letters - GuruFocus
Hims & Hers down as FDA targets GLP-1 compounders (HIMS:NYSE) - Seeking Alpha
US FDA warns 30 telehealth firms over misleading ads for compounded weight‑loss drugs - Reuters
Hims & Hers Health's Options Frenzy: What You Need to Know - Benzinga
Hims & Hers Health: Leaving GLP-1s Behind (NYSE:HIMS) - Seeking Alpha
HIMS Pharmacy Partner to Relaunch Compounded Version of Wegovy - GuruFocus
Strive Pharmacy says it will not resume compounded oral semaglutide sales - Reuters
Hims & Hers Health stock price forecast: Bearish momentum persists as HIMS slides 5.34% - Traders Union
Can Hims & Hers Overcome the FDA’s GLP-1 Crackdown? - TipRanks
Hims expansion may not come in time for risky GLP-1 business - Reuters
Hims & Hers Stock (+13%) : MS Conf Reassurance Sparks Short Squeeze - Trefis
United StatesK&L Gates Advises Blackbird Ventures on Eucalyptus Sale to Hims & Hers Health, Inc. - Mondaq
Insider Sell: Soleil Boughton Sells Shares of Hims & Hers Health Inc (HIMS) - GuruFocus
HIMS: Personalized care, tech-driven growth, and global expansion fuel strong revenue and margin outlook - TradingView
Hims & Hers Health (NYSE:HIMS) Stock Price Up 10.5%Should You Buy? - MarketBeat
Hims & Hers Surges on Strong Results and Strategic Acquisitions - StocksToTrade
Why Hims & Hers Health (HIMS) Is Down 6.4% After New Shelf Filing And Regulatory Scrutiny - Yahoo Finance
What's Behind The Jump In Hims & Hers Health Stock? - Benzinga
Glancy Prongay Wolke & Rotter LLP Announces Investigation of Hims & Hers Health, Inc. (HIMS) on Behalf of Investors - The AI Journal
Check Out What Whales Are Doing With HIMS - Benzinga
Hims & Hers stock rises 3.93% as technical indicators show strong selling pressure - Traders Union
What is behind Hims & Hers Health recent gain in value today - Traders Union
Hims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore - AOL.com
PacBio, Myriad Genetics, LeMaitre, Hims & Hers Health, and GoodRx Shares Are Falling, What You Need To Know - Finviz
Hims & Hers Expands Digital Health and Global Platform Strategy - The Globe and Mail
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know - Yahoo Finance
Hims Faces GLP-1 Scrutiny While Broader Telehealth Growth Story Evolving - Yahoo Finance
Zacks Research Upgrades Hims & Hers Health (NYSE:HIMS) to "Hold" - MarketBeat
Down 70% Over the Past Year, Can Hims & Hers Health Stock Bounce Back? - Nasdaq
Got $5,000? Hims & Hers Could Be a Direct‑to‑Consumer Health Moonshot in the Making - Nasdaq
HIMS Stock Price, Quote & Chart | HIMS & HERS HEALTH INC (NYSE:HIMS) - ChartMill
How Investors Are Reacting To Hims & Hers Health (HIMS) Softer GLP-1 Outlook And ESOP Share Offering - simplywall.st
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.55%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):